Published in Antisense Nucleic Acid Drug Dev on October 01, 1997
Surface expression of Toll-like receptor 9 is upregulated on intestinal epithelial cells in response to pathogenic bacterial DNA. Infect Immun (2007) 1.35
'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res (2002) 1.08
A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun (2006) 1.08
Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A (2005) 1.06
A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A (2003) 0.98
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res (2003) 0.98
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol (2010) 0.95
Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother (1999) 0.88
Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. Nucleic Acids Res (2002) 0.88
Exploring Internal Ribosome Entry Sites as Therapeutic Targets. Front Oncol (2015) 0.78
Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN. Neoplasia (2004) 0.78
Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res (2006) 0.78
CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin. Exp Dermatol (2015) 0.77
Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother (2008) 0.75
CpG-ODN Class C Mediated Immunostimulation in Rabbit Model of Trypanosoma evansi Infection. PLoS One (2015) 0.75
Impact of site-specific nucleobase deletions on the arthritogenicity of DNA. Inflammation (2004) 0.75
Detection of nucleic acid hybridization by nonradiative fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (1988) 4.90
A protein that specifically recognizes the 3' splice site of mammalian pre-mRNA introns is associated with a small nuclear ribonucleoprotein. Cell (1986) 4.57
Efficient methods for attaching non-radioactive labels to the 5' ends of synthetic oligodeoxyribonucleotides. Nucleic Acids Res (1986) 4.12
Sequence identity of the n-1 product of a synthetic oligonucleotide. Nucleic Acids Res (1995) 3.88
Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1988) 2.85
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A (1991) 2.76
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother (2006) 2.75
Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem (2005) 2.14
Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci U S A (1988) 2.09
Laparoscopic assisted transversus abdominis plane block: a novel insertion technique during laparoscopic nephrectomy. Anaesthesia (2011) 1.98
Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int (2008) 1.97
Barriers to treatment: why alcohol and drug abusers delay or never seek treatment. Addict Behav (1993) 1.93
Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol (1996) 1.87
Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord (1999) 1.83
A prospective study of conventional transbronchial needle aspiration: performance and cost utility. Respiration (2010) 1.66
Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci U S A (1992) 1.59
Local anaesthesia: to warm or alter the pH? A survey of current practice. J R Coll Surg Edinb (1999) 1.58
Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci U S A (1996) 1.58
Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study. Int J Tuberc Lung Dis (2004) 1.58
The association between narcolepsy and REM behavior disorder (RBD). Sleep Med (2005) 1.56
Are patients who undergo open-access endoscopy more anxious about their procedures than patients referred from the GI clinic? Am J Gastroenterol (1996) 1.53
Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Res (1993) 1.53
Cross-cultural evaluation of two drinking assessment instruments: alcohol timeline followback and inventory of drinking situations. Subst Use Misuse (2001) 1.53
Ocular myocysticercosis: an unusual case of ptosis. Nepal J Ophthalmol (2013) 1.47
GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev (1992) 1.45
Use of parenteral methotrexate significantly reduces the need for biological therapy. Rheumatology (Oxford) (2007) 1.43
Use of transillumination technique for venous cannulation in paediatric patients under anaesthesia. Singapore Med J (2010) 1.41
The in vitro-synthesized RNA from a cDNA clone of hepatitis E virus is infectious. J Virol (2000) 1.40
Zosteriform and disseminated lesions in cutaneous leiomyoma. Acta Derm Venereol (2001) 1.40
Percutaneous treatment of catheter-induced dissection of the left main coronary artery and adjacent aortic wall: a case report. Catheter Cardiovasc Interv (2000) 1.35
Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther (1995) 1.34
New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol (2000) 1.32
Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A (1998) 1.30
A comparison of a brief and long version of the Situational Confidence Questionnaire. Behav Res Ther (2000) 1.27
Alcohol abusers who want to quit smoking: implications for clinical treatment. Drug Alcohol Depend (1999) 1.27
Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet (1995) 1.23
Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem (2001) 1.23
Dual blockade of cyclic AMP response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. gene-specific inhibition of tumor growth. J Biol Chem (1999) 1.20
Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci U S A (1993) 1.19
Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates. Antisense Res Dev (1994) 1.17
Heat shock protein 70 prevents secretagogue-induced cell injury in the pancreas by preventing intracellular trypsinogen activation. J Clin Invest (2000) 1.15
Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev (1994) 1.14
Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant (2004) 1.13
TM Finder: a prediction program for transmembrane protein segments using a combination of hydrophobicity and nonpolar phase helicity scales. Protein Sci (2001) 1.12
In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci (1997) 1.12
Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res (2001) 1.12
Cloning, sequencing, and expression of the hepatitis E virus (HEV) nonstructural open reading frame 1 (ORF1). J Med Virol (2000) 1.12
Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A (1999) 1.09
Retinal complications associated with hyperviscosity in chronic lymphocytic leukaemia. Intern Med J (2008) 1.08
Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistant Plasmodium falciparum. Proc Natl Acad Sci U S A (1992) 1.07
Fostering self-change among problem drinkers: a proactive community intervention. Addict Behav (1997) 1.06
Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol (1996) 1.04
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem Pharmacol (1995) 1.04
Single-strand-targeted triplex formation: stability, specificity and RNase H activation properties. Gene (1994) 1.03
Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant (1994) 1.03
Improvement in the synthesis of oligonucleotides of extended length by modification of detritylation step. Nucleic Acids Res (1994) 1.03
Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev (1993) 1.02
T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat (2007) 1.01
Sequencing of synthetic oligonucleotides and analogs by homopolymeric tailing. Nucleic Acids Res (1995) 1.01
An evaluation of densitometric vertebral fracture assessment in men. Osteoporos Int (2007) 1.01
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol (1995) 1.00
New methods for assessing T-cell responses. Clin Diagn Lab Immunol (2000) 1.00
Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci U S A (1994) 1.00
Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med (1999) 1.00
Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs (2001) 0.99
Influence of activating and inhibitory killer immunoglobulin-like receptors on predisposition to recurrent miscarriages. Hum Reprod (2009) 0.99
Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett (1999) 0.99
Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol (2009) 0.98
Method for sequencing synthetic oligodeoxynucleotide phosphorothioates. Anal Biochem (1993) 0.98
Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett (2000) 0.97
Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. Antisense Nucleic Acid Drug Dev (1998) 0.97
Translocation of the pAntp peptide and its amphipathic analogue AP-2AL. Biochemistry (2001) 0.97
Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A (1990) 0.97
Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther (2001) 0.97
Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity. Eur J Biochem (2001) 0.96
Post-kala-azar dermal leishmaniasis in Nepal. Int J Dermatol (2001) 0.95
Maternal di-(2-ethylhexyl)-phthalate exposure influences essential fatty acid homeostasis in rat placenta. Placenta (2008) 0.94
Studies with inorganic ion-exchange membranes. Talanta (1978) 0.94
Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol (2004) 0.93
Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg Med Chem Lett (1998) 0.93
Cleansing efficacy of commercial denture cleansers: ability to reduce Candida albicans biofilm activity. Int J Prosthodont (1996) 0.93
Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther (1996) 0.93
NMR structure of a 2',5' RNA favors A type duplex with compact C2'endo nucleotide repeat. Biochem Biophys Res Commun (2001) 0.93
Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem (2001) 0.93
Systemic lupus erythematosus and tuberculosis: a review of complex interactions of complicated diseases. J Postgrad Med (2010) 0.92
Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem (2001) 0.92
Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy. Tissue Antigens (2004) 0.92
Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem (2001) 0.91
Day-surgery laparoscopic cholecystectomy: factors influencing same-day discharge. World J Surg (2008) 0.91
Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett (2001) 0.91
Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett (2000) 0.91
Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res Dev (1994) 0.91
Incorporation of multiple reporter groups on synthetic oligonucleotides. Nucleic Acids Res (1990) 0.91
Oligonucleotides containing G.A pairs: effect of flanking sequences on structure and stability. Biochemistry (1995) 0.90
Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo- and 3'-5'-deoxyribonucleotide segments. Nucleic Acids Res (1997) 0.90